GHK-Cu

What the compound is

GHK is the three-amino-acid sequence glycyl-L-histidyl-L-lysine. It binds copper, producing the complex commonly called GHK-Cu. The foundational literature concerns cell signalling and connective-tissue turnover. Finding a peptide in human biology is useful mechanistic context, but is not evidence that adding it externally produces a net health benefit. [1]

Why collagen researchers study it

Maquart and colleagues reported increased collagen synthesis in cultured fibroblasts. The change was not explained simply by an increase in cell number. This supports a laboratory hypothesis about matrix production, but a cell-culture concentration does not specify an effective serum formulation or a safe human exposure. [1]

In a later rat wound-chamber experiment, investigators found greater accumulation of collagen and other matrix components after local exposure to GHK-Cu. Wound chambers are controlled experimental environments; they do not reproduce all the features of ageing facial skin or chronic wounds in people. The meaningful result is a change in matrix biology in that model. [2]

The evidence is not uniformly positive

Another experiment examining guinea-pig wounds and fibroblasts reported slower tissue reorganisation and delayed fibroblast activation with the copper-peptide complexes. Differences in models, timing and endpoints can produce different findings. This is a reason to explain the evidence carefully, rather than present every wound experiment as confirmation of faster healing. [3]

A randomised study of care after carbon-dioxide laser resurfacing had 13 completers. Blinded and computer-based assessments did not show significant advantages for redness resolution, wrinkles or overall skin quality. Patient-reported satisfaction was higher in the GHK-Cu group. A subjective signal alongside negative objective comparisons is a mixed result, not definitive proof of wrinkle reduction. The small study also cannot settle all questions about other topical formulations. [4]

Human research context: serum and vial

The directly relevant human study reviewed here used topical skincare after a procedure. It does not validate systemic administration or a different finished serum. [4] Leni currently lists both a 50 mg vial and a copper serum. Those are separate presentations of a related ingredient story, not interchangeable interventions. Serum concentration, complete ingredients, stability and delivery vehicle need their own documentation. A vial label is likewise not evidence of sterility, purity or suitability for injection. [6]

No self-use protocol follows from these papers. For a finished topical product, any instructions would need to come from verified formulation-specific information, rather than being reconstructed from a laboratory paper.

Safety and the next useful questions

The FDA identifies limited human safety information and potential immunogenicity concerns for injectable GHK-Cu. This injectable-route assessment should not be presented as a trial of Leni’s serum. [5]

The useful next research step is a well-controlled evaluation of an explicitly characterised formulation: defined endpoints, an appropriate vehicle comparator, blinded assessment and adequate follow-up. Collagen markers, participant satisfaction and visible clinical change should be reported separately. For this library, the justified conclusion is that GHK-Cu has a mechanistic research basis and limited clinical evidence, with substantial uncertainty about generalisation across products and routes. [1][4]